Dynavax delivered robust Q2 2025 results, achieving record quarterly net product revenue for HEPLISAV-B of $91.9 million, a 31% increase year-over-year. The company reported a GAAP net income of $18.7 million and an EPS of $0.14 diluted. HEPLISAV-B's U.S. market share increased to approximately 45%.
Record HEPLISAV-B quarterly net product revenue of $91.9 million, up 31% year-over-year.
HEPLISAV-B's U.S. market share increased to approximately 45% in Q2 2025.
GAAP net income of $18.7 million and diluted EPS of $0.14 for the quarter.
Refined full-year 2025 HEPLISAV-B net product revenue guidance to $315 million to $325 million.
Dynavax refined its full-year 2025 HEPLISAV-B net product revenue guidance and expects continued progress in its clinical pipeline.
Analyze how earnings announcements historically affect stock price performance